Keyword results: SBTX

Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Am I panicked by Skinbiotherapeutics?

I am more panicked by the IRA man objecting to my bonfire. Heck, it is not as if it were the 12th July, and I were wearing my bowler hat with an orange sash, is it? In today's podcast, I look at Skinbiotherapeutics (SBTX); Eurasia (EUA) and a Kraut moron; Supply@ME Capital (SYME); and Argo Blockchain (ARB). 

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast - lied to by Barclays, and fleeced by EasyJet

I discuss both these corporates, and remind the 94% of you yet to support Rogue Bloggers for Woodlarks: please do so, HERE.  Then, I discuss Stuart Ashman of Skinbiotherapitics (SBTX), who has made me look like a complete git (again), as he withdraws from ShareStock. But, I will announce another BIG-name speaker tomorrow, and will replace Stuart. So, make sure you book your tickets, HERE.  Then, I look at Cellular Goods (CBX) and Guild ESports (GILD), the David Beckham dogs. 

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – following recent developments, how does the valuation stack up?

Shares are now ‘ex-dividend’ for Optibiotix’s ‘ProBiotix Health’ business, which will be spun off onto the AQSE Growth Market – with an associated fundraise – at the end of this month. Additionally, SkinBioTherapeutics (SBTX), in which it has a 20.73% stake, has just announced half-year results – that the market did not like. So, how does the valuation stack up now?

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Warned that I must not talk about sucking PR cock even with reference to the FT which does!

Apparently, the chap from the FT may object to me reminding those at the April 5 Woodford event that his paper, like the wretched Mail on Sunday, Daily Mail, Sunday Times et al DID suck Woodford’s PR cock.  Elsewhere, I discuss Red Rock Resources (RRR); Skibiotherapeutics (SBTX); Amigo (AMGO); Avacta (AVCT); Inspirit (INSP); and Mirriad Advertising (MIRI).

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics – interim numbers & warning of slight delay largely irrelevant, the clear potential remains - Buy

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: A night of shame for Mello Events, and Skinbiotherapeutics - I'm buying more

I start with Mello Events, which last night exposed itself as a PR promoter, failing to allow any questions about the elephant in the room: musicMagpie(MMAG).  Then to Optibiotix (OPTI) and Skinbiotherapeutics (SBTX), after today’s news from the latter. I have spoken to both Steve O’Hara and Stuart Ashman. As Les points out in the comments section, the silver lining for you is the postponement of my retirement – but not for long. The market has over-reacted: long-term, these two companies will subsidise the goat farm, as I explain in detail.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

TomWinnifrith Bearcast: My SIPP buys more Optibiotix, Bluebird vs Kefi, & much more

This is a very long podcast, covering: Optibiotix (OPTI); Skinbiotherapeutics (SBTX); Kefi (KEFI); Bluebird (BMV); Ten Lifestyle (TENG); CakeBox (CBOX); Deepverge (DVRG); Petropavlovsk (POG); Eurasia (EUA); and Amur Minerals (AMC).

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: I start the expose of a new well known zero in waiting tomorrow but here are three to tuck into first

Forgive the voice. Last week’s cold has left me sounding like I have been swallowing gravel. I start with a few words about distractions today which included ordering 72 blackthorn plants and 12 wild blackberry bushes and fetching antique Welsh furniture to go to Greece. Then I ponder whether Nigel is reinvesting his Ariana (AAU) dividends in Ariana (AAU).I explain why I am not and where I am putting the cash. Or  rather I am sitting on the fence between Optibiotix (OPTI) and Skinbiotherapeutics (SBTX). The 3x company I mentioned on Saturday, is a well known one and will be exposed via a multi-part series kicking off tomorrow at 8.30 AM and it is, I am sure, a zero.  Ahead of then I discuss what makes a real bear market and how it affects rubbish stocks out of cash. Until you see  a good few RNS statements each month saying that “shares are suspended pending clarification” you are not in a bear market.  In that vein, I mention three POS companies which RIGHT NOW have no cash and are burning it: Vast Resources (VAST), Chill Brands (CHLL) and Supply@ME Capital (FRAUD) and I discuss the next steps for that trio and why the net is tightening on them.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Optibiotix & chatting to Steve O'Hara as Lemming Investor walks away

There was no Bearcast yesterday as I was a) knackered after a tough Rogue Bloggers for Woodlarks training walk and then b) a bit pissed after Ireland’s triumph over the infidels. You can now donate to the 2022 Rogue Bloggers walk on June 11 HERE. In today’s podcast I discuss Optibiotix (OPTI), a long chat with Steve O’Hara and an, in my view, mistaken, but for him massive, call by Lemming Investor. I also cover SkinBiotherapeutics (SBTX). The Russia/Ukraine podcast I refer to is HERE

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: The rank Nigel Farage hypocrisy, Hitchens, Syed, Nimmo and the great Chris Bailey

I take a tour through four weekend press articles starting with that greedy scumbag Nigel Farage – I refer in the podcast to THIS PIECE. Then to two great pieces on Ukraine and on the decadent West by Peter Hitchens and Matthew Syed respectvely before discussing the Sunday Times article on CBD and pot stocks. Finally I discuss Chris Bailey’s excellent piece on this website and my own approach to shares I own, mentioning Skinbiotherapeutics (SBTX) and some news breaking in the USA.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Sitting on the fence with Lucian Miers

I start with Ukraine, Russia and all that macro shite and say afew things which challenge the Western narrative and which some of you may disagree with violently. I cover Ferrexpo (FXPO),Amur (AMC) and Eurasia (EUA) in this section. I mention Cineworld (CINE) and then discuss today’s news from Optibiotix (OPTI) and, en passant, Skinbiotherapeutics (SBTX) where I am buying more shares this afternoon. 

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics – “Business update”, expect shares to respond positively on further updates soon: BUY!

SkinBioTherapeutics (SBTX) has published a Business update” announcement including that it has now progressed to the second phase of its AxisBiotix-Ps food supplement for psoriasis product commercialisation strategy and that the SkinBiotix active ingredient project with Sederma is on track. Sounds good!

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast - Accepting the resignation of Peter Brailey as there is a line in the sand

I want to be 100% transparent with you so I explain why, as of 8 AM today, Peter is no longer a member of this parish after apologising for yesterday’s poor sound quality for which there was a good reason. I look at two shocking economic statistics and what they mean. I then cover: SkinBiotherapeutics (SBTX), Bluebird Merchant Ventures (BMV),  AEX Gold (AEXG), Novacyt (NCYT), Avacta (AVCT) and Cake Box (CBOX). 

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Just how do market makers work and set prices

I am asked this question by a long suffering reader in relation to Skinbiotherapeutics (SBTX) and do my best to answer. I look at IQE (IQE),the curious share dealing of Mr Drew Nelson and whether I’d be tempted. I still see no sign of the IPO of Zak Mir’s crazy media investment company which he said was imminent two weeks ago. Is it Lift off?  I comment on Bluebird Merchant Ventures (BMV)  and then have a detailed look at Sarah Willingham’s Nightcap (NGHT) in light of today’s expose. It really is a one way bet. Down. 

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: the greed of Piggy Austin is just not acceptable

I start with a few thoughts on a visit this morning to the post industrial wastelands of Salford. Gosh it was grim.  Then a schoolboy error on Skinbiotherapeutics (SBTX) but it only makes the case  for filling your boots stronger. No, I have not got a scooby about why Bluebird (BMV) shares are up but I speculated and put together a few pieces of the jigsaw.  I look at W Resources (WRES) but would not touch it with a bargepole and then discuss the wholly unacceptable greed of Andrew “piggy” Austin at Kistos (KIST)

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bonus Bearcast - why I think Skinbiotherapeutics is a 10 bagger (or more) from here

As you know I am reviewing my pension as discussed HERE. As such I am chatting to various CEOs who I have backed and yesterday evening I had a long chat with Stuart Ashman of Skinbiotherapeutics (SBTX). He is not a bluffing promoter but, I believe, a sober and grounded chap. I came away from the call just incredibly excited. I explain why the share price is where it is but also why this could within a couple of years be a 10 bagger but it could equally be a 20 bagger. Certainly any free cash within my SIPP will, even at twice today’s price be going into this stock. And if I am right there is a clear implication for Optibiotix (OPTI) so I am not selling any shares in it either.  Footnote/correction. There are not 2 million psoriasis sufferers worldwide as per podcast but 120 million. I can’t say that weakens the case!

Subscribe to ShareProphets to access Premium Content

OptiBiotix Health – “Commercial and strategy update”. What does it mean tangibly? It means BUY

OptiBiotix Health (OPTI) has made what it describes as a Commercial and strategy update”, including arguing “look forward with confidence to further commercial progress of the group in the current year and beyond”. What does that though mean tangibly?

PREMIUM CONTENT

OptiBiotix Health and SkinBioTherapeutics – further progress & triggers for dramatic 2022 re-rate

OptiBiotix Health (OPTI) was one of our tips of the year, with we anticipating financial progress as its deals for its compounds expand and further deals kick-in. It has now announced that a further human volunteer study on its cholesterol-reducing probiotic LPLDL - on a different population group of hypercholesterolemic adults – has shown “at six weeks, when volunteers taking placebo were compared to those taking LPLDL, there were statistically significant changes to clinically important cardiovascular risk”, including “34.2% reduction in total cholesterol (p=0.001)”.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Dissecting the accelerating share price collapse at the fraud Chill Brands as I report a crime against me to the Police

Okay the crime is not as exciting as it sounds and was not, as far as I know, perpetrated by some Bulletin Board loon. After discussing that I look at Chill Brands (CHLL), Brave Bison (BBSN) and Skinbiotherapeutics (SBTX)

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics – full-year results, still a “transformational” progress Buy?

SkinBioTherapeutics (SBTX) has announced results for its year ended 30th June 2021 emphasising “transformational” progress. So what is this?

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Chatting to Stuart Ashman, making a share purchase and meeting a psychic moron

In today’s podcast I discuss why I worry that my wife may have become a real housewife of posh Cheshire, not the part where they play rugby league. Then I look at ADM Energy (ADME) and that RNS reach issue again, tell you about a psychic moron who owns shares in Supply@ME Capital (SYME) and then I discuss, at length, Skinbiotherapeutics (SBTX) after a chat with CEO Stuart Ashman today and on the back of that I have bought more shares in the company.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith bearcast - the dossier that made my skin crawl

I do not name the company but the dossier is one one of the journalists here. It concludes that he has done nothing wrong but it goes through utterly uncalled for very personal details about him, his world view, his girl friend, his work and more. It made my skin crawl and the company that spunked £40,000 on this document should be utterly ashamedof itself. I have put in a call and let it know that behaving like this towards one of our journalists is asking for a lot of trouble. It is repellant and I am on the warpath.  I then look at theSP Angel/Union Jack Oil (UJO) scandal, at Nanosynth (NNN), Powerhouse (PHE) explaining the RNS/RNS Reach issue in full.Finally I discuss Skinbiotherapeutics (SBTX). 

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: A tale of 2 death spirals and is even Evil Knievil still friends with Amigo? If so why?

In today’s podcast I look at Vast Resources (VAST) and why you should read an RNS closely and at Supply@ME Capital (SYME) as I get my dates confused and so, it seems, does it. I consider Eurasia Mining (EUA) – surely a statement needed. I look at Skinbiotherapeutics (SBTX) and at Amigo (AMGO) where surely even Evil must concede defeat at the hands of the FCA on whose side I am on, in this matter at least.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics – OptiBiotix’s share sale, who does it think it’s kidding?

Having been falling from early this month, shares in SkinBioTherapeutics (SBTX) are currently further lower after it announced “OptiBiotix Health Plc has placed 3,636,363 ordinary shares in SkinBioTherapeutics with new and existing institutional investors at a price of 55 pence per share”. With SkinBioTherapeutics CEO Stuart Ashman though arguing “the company is going from strength to strength” and “it is important to attract new investors who are keen to come on board to support us in the next stage of the company’s development, as a commercial entity”, why the further share price fall?

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast - a helpful graphic explaining the Cineworld smoke and mirrors today

I record from the Welsh Hovel which is once again a building site. Excuse any background noise. I look at Wildcat Petroleum (WCAT) and its uncorrected and untrue 4 October RNSThen at the fraud Chill Brands (CHLL). In both cases the regulator, the hapless FCA, should be acting right now. Then it is onto Cineworld (CINE) and, with the graphic below – hat tip EB. I explain why its trading statement is so deceptive and why the shares are still a sell. Finally a few words on Optibiotix (OPTI) & Skinbiotherapeutics (SBTX) and today’s confirmation of what a good journalist I am. What does it mean for both stocks?

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Stuart Ashman, Steve O’Hara, posh PR bird Melanie, and scumbags Cenkos – institutional investors my arse!

As predicted HERE the print going through late on Friday was Optibiotix (OPTI) dumping £2 million worth of Skinbiotherapeutics (SBTX) at 55p. I told you that this would happpen weeks ago producing more bluster and fake denials from all involved. Fuckers! The release this morning insults the intelligence of we loyal shareholders in both companies yet again. Stuart, Steve, posh PR bird Melanie Toyne-Sewell and the scumbags at Cenkos do you think we are idiots? You treat us as if we are.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Optibiotix dumping 3.75m of Skin shares on Friday?

I predicted that this was the plan and such a trade went through on the prints late on Friday. Both Optibiotix (OPTI) and Skinbiotherapeutics (SBTX) have declined chances I have offered ( two for Opti) to deny the trade was as I speculate. So where does this leave shareholders in both companies and the, badly advised by scumbags Cenkos, Steve O’Hara?  

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: its V Day!

I start with the two companies beginning with V and articles on this website today: Versarien (VRS) has responded, weakly to this expose. Vast Resources (VAST) cannot respond to this bombshell which exposes the cancer at the heart of AIM Regulation again and makes the shares uninvestable at any price. Then I look at Ben’s Creek (BEN), Skinbiotherapeutics (SBTX) on product launch day and at Central Copper where an IPO that should be pulled is delayed again. 

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Am I wrong about Supply@ME Capital and how do you know if Andrew Prelea of Vast is lying?

I start with a few notes on horticulture here in Wales then move onto questioning my strongly held belief that Supply@ME Capital (SYME) is a worthless fraud. Then I explain why the recent Cenkos note on Skinbiotherapeutics (SBTX) is wrong and how, via its website, the company faces an acid test. Actually the website I refer to has now been amended as you can see HERE. But not before my contact placed an order.  Finally I look at Vast Resources (VAST) and its shocking placing followed by even more shocking no-one is watching O’clock results.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Am I wowed by the Skinbiotherapeutics presentation and what about the elephant in the room

I deal with Skinbiotherapeutics (SBTX) first.  Then it is onto Yourgene (YGEN) and its trading statement, Eurasia (EUA) and a two year farce and finally the bid for Arden (ARDN) by Ince Group (INCE) and what to make of it all. I feel uncomfortable for reasons I explain.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: an unpriced option to buy 80% of a business with no given profits at no specified cost is worth what?

In today’s Bearcast, I look at Skinbiotherapeutics (SBTX), Optibiotix (OPTI), Kefi (KEFI), Nightcap (NGHT), VAST Resources (VAST) and finally at my old pal Richard Poulden’s Valereum Blockchain (VLRM), the current love interest of Big Dave Lenigas. 

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Optibiotix vs Skinbiotherapeutics again - short one long the other?

I have a few words on Malcolm’s article of earlier which, by definition, makes me old according to him. Pot. Kettle. I talk about the general mood of insanity. Then, in that context, I look at the Optibiotix (OPTI) vs Skinbiotherapeutics (SBTX) debate. Should one short one and go long the other as PL has suggested? I discuss what I am doing and why.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – shares nudge ahead on interims, much more to come

Life sciences compounds developer OptiBiotix Health (OPTI) has announced results for the first of calendar 2021, emphasising “sales of LPLDL and SlimBiome of £1.076m, a 44.5% increase over H1:2020… pleasing given the continued uncertain global economic environment and challenges of the subsequent waves of COVID-19, particularly in countries like India and the USA. The shares have currently responded slightly higher, to 50p.

Subscribe to ShareProphets to access Premium Content

SkinBioTherapeutics – announces AxisBiotix-Ps launch date, high margin profit potential moving closer - we are 289% ahead but much more to come

As things stand at 69p, we are 289% ahead on this share tip but there is much more to come. SkinBioTherapeutics (SBTX) has announced its probiotic food supplement to help alleviate the symptoms of psoriasis, AxisBiotix-Ps, is to launch on 29th October, following highly positive results from its consumer study in May and key commercialisation activities since.

PREMIUM CONTENT

UPDATED: Buckets and buckets of jam tomorrow and can you feel the Tom Winnifrith hate in that Optibiotix seminar Q&A

This event was held on 9 September and what follows is a transcript of the more interesting Q&As. There is oodles of jam tomorrow but I sense that the time for that working has passed. Steve O’Hara and Optibiotix (OPTI) need to start delivering jam today to drive a re-rate of any sort, let alone from £50 million to £1 billion as suggested in Q1.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics – ‘Business Update’, high margin profit potential moving materially closer

SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30th June year-end cash totalled £4.6 million. Sounds good.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: But for a fluke the ceiling would have fallen in on my head and on the cats

I discuss two developments at the Welsh Hovel. There is great news HERE but also a bit of a disaster which could have been fatal for the cats and bad for me. Then I look at backing proven failures or chaps who wave red flags mentioning Sensyne (SENS), Nigel Wray, me and a few others. That leads me on to the wall of silence from Central Copper Resources about its AIM IPO and me explaining what is really going on, notably at broker Brandon Hill. Finally I look at today’s news from Skinbiotherapeutics (SBTX) and where, as a result, I expect its shares to be at Christmas.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Two Beauties and three wretches

I start with a discussion on the forest fires in this region of Greece then move onto the impending total humiliation of Julie “Lingerie on Expenses” Meyer after today’s shocker HERE. Then I look at Supply@ME Capital (SYME) asking if its boss owns any shares at all. He certainly does not own 26% as claimed. Then I look at the Optibiotix (OPTI) trading statement  discussing it and Skinbiotherapeutics (SBTX). Finally back to a wretch: Versarien (VRS) and its shite results which show why we must get Ian Westbrook over the line – he is now, with a slightly extended deadline – just £1775 shy of making the loathsome Neill Ricketts sweat in court. Please keep giving those tenners and twenties HERE

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – 2020 results and company chat, Strong Buy - 200p+ within 30 months

OptiBiotix Health (OPTI) has announced its 2020 calendar year results, emphasising improving financials and that it is well placed to exploit a now established low overhead, sustainable business model. It is what we learned in a chat with Steve O’Hara that makes us flag this up as such a STRONG BUY.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics – positive study results suggest this could be a six bagger from here!

SkinBioTherapeutics (SBTX) has announced the results of the AxisBiotix-PsT consumer study of patients suffering from psoriasis and it says that it will now be seeking regulatory approval for the product as a food supplement in parallel in the UK, US and Europe… targeting a commercial launch of theAxisBiotix-Ps™ product in Q4 2021”.  Do the maths! This is going to be massive.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Apparently I know nothing about tax

Okay, tomorrow is the big day. If you are yet to donate please do so HERE as the Rogue Bloggers are now just over £2,000 off target. In today’s podcast, I discuss at length issues arising from the Skinbiotherapeutics (SBTX) and Optibiotix (OPTI) issue where Steve O’Hara says a man who took a company to the Isle of Man knows nothing about tax! Then onto the fraud Zoetic (ZOE), company specific issues and the wider one, raised by promoter David Lenigas today, of the increased risk caused by margin buying of small caps.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Why will Zoetic not answer this 1 question?

The good news is that Rogue Bloggers for Woodlarks is, 3 days ahead of our walk, now less than £3,000 away from our £48,000 fund raise target. If you are yet to donate, please do so HERE. In today’s podcast, I discuss Amigo (AMGO), Wishbone Gold (WSBN), Zoetic (ZOE), Skinbiotherapeutics (SBTX) and Optibiotix (OPTI).

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Photo Bearcast: the Police come to visit me at the Welsh Hovel

Oh dear. What have I been accused of now? All is revealed in the photos below. I end by thanking you all as we are now at nearly £40,000 for Rogue Bloggers for Woodlarks. Thanks to all who have donated. To those still to chip in, as we are just c£8,000 short, please do so HERE. Sunday’s training walk will be the most grim yet. In the podcast, I look at Amigo (AMGO), Evil Knievil’s “scum” comment, Hurricane Energy (HUR), Skinbiotherapeutics (SBTX) and Novacyt (NCYT).

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics – new research programme adds to the vast potential but its looming Winclove results which are the key

Noting that “there is now an extensive growing body of research demonstrating direct links between the microbiome and the immune system, and consequently skin health”, SkinBioTherapeutics (SBTX) announced, a couple of weeks ago, initiation of a research programme with the University of Manchester. This is good news but not the elephant in the room!

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Optibiotics vs Skinbiotherapeutics

I start with a few words on the late Phil the Greek and reference an article I wrote exactly one month ago HERE on the liberal US celeb Joy Behar calling out Phil and his family as Nazis.  I reflect on the weather here in Wales and how tomorrow’s 20 mile training walk for Woodlarks will be very unpleasant indeed. So please do support me with a donation HERE. Then I discuss the saintly Vin Murria and share sales at Summerway (SWC) and for the first and last time in history I am a bit uneasy about all of this. Then the debate on whether to back the Skinbiotherapeutics (SBTX) or the Optibiotix (OPTI) charger? 

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics – new research programme - we are already 250% up but far more to come

Noting that “there is now an extensive growing body of research demonstrating direct links between the microbiome and the immune system, and consequently skin health”, SkinBioTherapeutics (SBTX) has announced initiation of a research programme with the University of Manchester.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: surely this is THE top of the market story to warn you

I start with a true story. Surely it is a cracking warning of the top of the market. Then onto the fraud Supply@ME Capital (SYMEconfirming my scoop. Finally a long discussion on the morality of breaking lock-ins ref Optibiotix (OPTI), Skinbiotherapeutics (SBTX) and Powerhouse Energy (PHE) run by sleazy ex Tory MP Tim Yeo.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBioTherapeutics interims – apologies for delayed update and an upgrade but I had to ponder

Notwithstanding the lock-in shenanigans with Optibiotix (OPTIdiscussed HERE, I am more bullish than ever. The results from Skinbiotherapeutics (SBTX) for the six months to 31 December 2020 came out on Monday. I apologise for the delayed update but I needed to ponder a while. What we read a few days ago was just excellent. Hence this upgrade.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Optibiotix – what is the point of a lock in agreement? Even a signed agreement from Steve O'Hara is worth jack shit

I think Optibiotix (OPTI) shares are very cheap as are those of Skinbiotherapeutics (SBTX) and am a loyal shareholder in both expecting to treble my money from here. Nor do I begrudge Optibiotix selling a few shares in Skinbiotherapeutics as it announced it had today as I imagine that will more than pay for a Nasdaq listing which may drive a re-rate. But I suggest that, in light of today’s events, a document signed by Steve O’Hara and Nomad and broker Cenkos is a worthless piece of toilet paper and both have legged over and deceived investors in Skinbiotherapeutics. Let me explain.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: I'd rather go hungry than drink this

Don’t get me wrong, I like the Optibiotix (OPTI) meal substitute drinks and do actually feel better after just a few days of losing a meal a day and a week of near zero carbs and no booze at all. But a serving suggestion from one reader went down very badly. Elsewhere I look at Sabien Technology (SNT) and the fallout from l’affaire Julie Meyer, Skinbiotherapeutics (SBTX) and also at Provident Financial (PFG).

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Optibiotix vs Skinbiotherapeutics the valuation gap explained + why it DOES matter if Eurasia and its shareholders break rules

A chap says he has made five hundred grand on Eurasia (EUA) so what does it matter if a few rules have been broken? I explain exactly why it matters and should matter even to him. Then I address why shares in Optibiotix (OPTI) are not reacting to the surging share price of Skinbiotherapeutics (SBTX). Natch I remain a loyal shareholder in both.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Irrational exuberance by you, irrational pessimism by me?

In today’s podcast I mention my planned Ha Ha then cover market madness, all the signs, Path Investments (PATH), Fast Forward (FFWD) and Skinbiotherapeutics (SBTX). And thanks for understanding about yesterday’s DOS attack.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Is this entrapment I see before me Charlotte dearest?

I start with communications received by email and twitter. I sense attempted entrapment by shareholders in the fraud Supply@ME Capital (SYME). Then it is onto a speech by Debbie Gupta of the FCA and her failure to understand why her organisation is not fit for purpose.  Then to Nightcap (NGHT), Petra Diamonds (PDL), Mountfield (MOGP), Skibiotherapeutics (SBTX) and me being fat as described here.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Peterhouse Corporate Finance wades into the transgender wars

A few words on the Budget then is Peterhouse staffed by woke loons or alt right freaks or both? I discuss in relation to Mountfield (MOGP). I look at Marchale (MAC), Iconic (ICON), Optibiotix (OPTI) and Skinbiotherapeutics (SBTX).

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – trading update and company chat, Buy

OptiBiotix Health (OPTI) has announced a trading update, emphasising “another year of progress… probiotic and functional fibre divisions achieving profitability”. The shares have though currently responded lower to 55.5p, so what’s the current situation here? We’ve spoken to Chief Executive Steve O’Hara and we believe that Mr Market has got this one wrong.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: £155k payoff plus shares for being a director for 1 month shocker!

In today’s podcast I look at Remote Monitored Systems (RMS), Online Blockchain (OBC), Zoetic (ZOE), Zenith Energy (ZEN) - after today’s bombshell expose -  ADVFN (AFN), Optibiotix (OPTI) and Skinbiotherapeutics (SBTX).

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Optibiotix - I think it has made a big accounting boo boo

I am a massive shareholder in Optibiotix (OPTI) and believe that I will do very well from my investment, where my average in price is c9p. The shares are now 61.5p mid and I think they will easily double from here within 18 months if not far sooner. But there can be no double standards here in the way that I cover companies, just because I own shares in them. I think the company has made a material accounting error which is also an own goal! Here’s why:

Subscribe to ShareProphets to access Premium Content
Price-Vs-Value

ShareProphets readers tips for 2021 competition – end January update

Having asked for readers tips for 2021 for the prize of 1/2 litre of Tom Winnifrith’s Greek Hovel olive oil (2021 harvest) HERE, the following is the first monthly update on performance (to be eligible needed to have selected, on a once per username basis, a buy & sell pick from the LSE or AIM casino and the stocks not to have been suspended at the commencement of 2021)…

Tom

Tom Winnifrith Video Shareshow No 15: Stuart Ashman runs what could be a 20 bagger and Lucian Miers on his longs and shorts

And now from Wales, by just 30 yards, it is my new weekly video show. This costs 99p per episode, and you can either listen to, or watch, some sparky interviews with Staurt Ashman of Skinbiotherapeutics (SBTX) where I am 130% up in seven months but think the shares could 20 bag from here and bear raider Lucian Miers on macro economics his cooling feelings on cold and warming feelings on bitcoin and his big longs and shorts. Then there are a few thoughts on companies you must NOT own, including the latest nonsense from the scallywags at Powerhouse Energy (PHE).You can access the show HERE

SkinBioTherapeutics – AxisBiotix study enrolment commences, set for a breakthrough year?

Making SkinBioTherapeutics (SBTX) one of our three tips of the year 2021, we noted we considered it likely to make 2021 a breakthrough year, including with a planned first quarter human study for AxisBiotix™ targeting psoriasis and then, subject to a positive readout, commencing commercialisation. Already we now have an Enrolment for AxisBiotix-PsT study commences” announcement and the shares are already massively higher than our 15.5p tip price at 29p. But you’d be mad to sell.

Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Another day of shame for AIM and why Sosandar is just not for me anymore

Today I look at three companies. I start with Skinbiotherapeutics (SBTX) where I ask if it is better to travel than to arrive? Then it is onto Sarah Willingham, Allenby Capital, The Sunday Times and their collective shame in the disgraceful AIM IPO of car crash in waiting Nightcap (NGHT). Finally I look at Sosandar (SOS).

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Rumour and counter rumour and Skinbiotherapeutics

Shares in this company, where I am a loyal shareholder, raced ahead to 33p on Friday.  The excitement was driven largely by a false rumour and in part, methinks, on a rumour that is true. This morning I had it confirmed that the false rumour was, er, false.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Steve O'Hara of Optibiotix blames interviews with me for share price weakness

Yup, if he does an interview with me and my tough questions, shares in Optibiotix (OPTI) go down.  So, going forward, it is only those paid-for interviews with folks like Proactive. “Steve, is your schlonger enormous or gigantic? Why are your shares so cheap? etc etc.” Whatever, I apologise to you all for asking the odd question. Without my malign influence, Optibiotix would clearly be in the FTSE 100. I discuss this company’s prospects and also those of Skinbiotherapeutics (SBTX) where I am also a loyal shareholder. I look at Trainline (TRN), Online Blockchain (OBC) and Vast Resources (VAST).

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Chatting to Steve O'Hara

In today’s podcast I look at Cineworld (CINE), Trainline (TRN), Novacyt (NCYT), Powerhouse Energy (PHE), Optibiotix (OPTI) and Skinbiotherapeutics (SBTX).

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Skinbiotherapeutics placing at 16p – why am I not impressed? But through gritted teeth a buyer

Skinbiotherapeutics (SBTX) boss Stuart Ashman until today held zero shares in the company. And he told us all that it had enough cash to last it until the end of next year at least.  And so now there is a £4 million placing and £500,000 open offer at 16p.  Mr Ashman can you see why I might be annoyed?

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: back in Wales no thanks to an AA confused by Sheep

I am back here at last and allow a bit of time for personal matters. Then it is on to Optibiotix (OPTI), Skinbiotherapeutics (SBTX), Verditek (VDTK) and G3 Exploration (G3E)

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – encouraging interims and CEO chat, Strong Buy

OptiBiotix Health (OPTI) is “pleased to present… results for the six month period ended 30 June 2020” and we have had a chat with CEO Steve O’Hara…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

SkinBiotherapeutics: more good news, increased targets upgrade of stance

Very excited shareholder Tom Winnifrith writes: On 26 May 2020, Steve and I tipped SkinBiotherapeutics (SBTX) at a 17.75p offer and at up to 20p with a target price of 30p. News last week suggests that, notwithstanding this company wasting a few grand a month employing the biggest knobhead in Christendom to do its PR, we were more than a tad conservative and the shares now trade at 22p-23.5p and are still dirt cheap.

Subscribe to ShareProphets to access Premium Content
Tom

Tom Winnifrith Shareshow No 6: 2 hours 17 mins of Richard Poulden on the collapse of the west and of empires, Kerim Sener of Ariana and me on Supply@ME capital and 6 more shorts

And now from Wales, by just 30 yards, it is my new, I hope, weekly video show. This costs 99p per episode, and you can either listen to, or watch some sparky interviews with Richard Poulden on the collapse of empires but also of the West at every level.  Also covered is the death of oil and how we should save our finances against such a backdrop and with Kerim Sener of Ariana (AAU). I also explain why Supply@ME Capital (SYME) is a crooked zero and I review the six short ideas from the previous five shows, one of which is already a zero. You can access the show HERE

SkinBioTherapeutics – “Business Update”, remains a buy...

SkinBioTherapeutics (SBTX) has updated that it is “very pleased with the progress that the company has been able to make during these most exceptional times”, particularly including “several months ahead of schedule, Winclove has now been able to successfully combine and formulate the blend as a probiotic food supplement, to be known as AxisBiotix ™Ps”...

PREMIUM CONTENT

Skinbiotherapeutics, the most idiotic of PR men and an email exchange

There are only two financial journalists who write regularly about Skinbiotherapeutics (SBTX): myself and Steve Moore. Coverage elsewhere is minimal to zero yet for some reason the company wastes the cash of loyal shareholders such as myself, on Instinctif, a financial PR firm.  Yesterday at 4.16PM on trading statement day Mr Phillip Marriage of Instinctif dropped me an email. I suspect he wishes he had not.  Our full exchange follows.

Subscribe to ShareProphets to access Premium Content
Tom

Tom Winnifrith Shareshow No 5: Well over 2 hours of Gary Newman on mining stocks, Harry Adams of Kefi and myself on why Cineworld has to be a stonking short

And now from Wales, by just 30 yards, it is my new, I hope, weekly video show. This costs 99p per episode to access and you can either listen or watch very sparky interviews with our Gary Newman on mining stocks to buy, why gold is NOT going to soar, a compelling £1.7 billion non-mining short and fishing shares, Harry Adams the boss of Kefi (KEFI) - a stock I own - and myself on why Cineworld (CINE) deserves to go bust, wont, but is a stonking short none the less. You can access the show HERE

Tom

Tom Winnifrith Shareshow No 3: Well over 2 hours of Peter Brailey on oil, gas and oil stocks, Skinbiotherapeutics CEO and myself on why Intu and Amigo will both be zeros

And now from Wales, by just 30 yards, it is my new, I hope, weekly show. This costs 99p per episode to access and you can either listen or watch very sparky interviews with our in house oil guru Peter Brailey not holding back with a new explicit warning on gas, Stuart Ashman of Skinbiotherapeutics (SBTX) who was so impressive I have just bought more shares and myself on how gravity cannot be defied forever with reference to zeros in waiting, Amigo (AMGO) and Intu (INTU).  You can access the show HERE

Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: the bosses at Photo-Me are complete bastards running a business you would not recreate

Okay, with three days to go to my 33.3 mile walk in the Welsh rain we need just £9,000 more to ensure Woodlarks survives. Thanks to all who have donated. If you have not done so please do so now HERE.  In the show today I discuss Restaurant Group (RTN), Quiz (QUIZ), the disaster now facing property investors, Skinbiotherapeutics (SBTX), UK Oil & Gas (UKOG) and Photo-Me (PHTM) where the bosses are total bastards. How dare the greedy so and sos treat poor old Malcolm Stacey like this?.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: correction on Skinbiotherapeutics share sale, an SP Angel insider dealing scandal? And is Opti's Steve O'Hara a liar like Bidstack's Draper?

I start with my training walk of yesterday for rogue bloggers for Woodlarks. i managed 12.5 laps before the sun got to me. In two weeks I must do 50. My next big walk is Tuesday - we are at 36% of target so please do donate HERE. Next up in hargreaves Lansdown (HL.), why not screw your customers as they seem to like it? Then onto share sales in Skinbiotherapeutics (SBTX) by Optibiotix (OPTI) and what appears to be a scandal involving broker SP Angel. I shall be going to the FCA tomorrow to ask for an enquiry. Finally is Steve O'Hara a liar like Lyin' James Draper of Bidstack (BIDS). Drunken Sailor who is suffering a GroupThink induced lockdown dementia thinks so and also that I am a ramper and should tell folks to sell. I discuss Drunken's concerns in light of a chat with O'Hara and an email from him which I read out.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: In defence of Boohoo's management

In today's podcast I tempt fate - as I am about to record a video with Matt Earl - in defending Boohoo's (BOO) boss. I discuss the shares vs cash debate, Rolls Royce (RR.), sharp share price moves, ref Skinbiotherapeutics (SBTX) and what the real unemployment number will be as furloughing is wound down. And now for a long training walk for the Woodlarks walk in 2 weeks time. We are now at 36% of target: please donate today HERE

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – further SkinBioTherapeutics shares sale reviewed

It has been announced OptiBiotix Health (OPTI) has sold 2.2 million further shares in 2017 spun-off onto AIM SkinBioTherapeutics (SBTX). This despite OptiBiotix’s results earlier this year including “SkinBiotherapeutics plc is making solid progress… As its partnership discussions turn into commercial agreements providing industry validation of its technology we anticipate SkinBiotherapeutics plc will grow in value, whereupon OptiBiotix shareholders will benefit from the appreciation of this asset”. So why the further sale?...

Subscribe to ShareProphets to access Premium Content
SQZ
SQZ

ShareProphets readers tips for 2018 competition - how's it looking with less than 3 weeks left?

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following updates on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

Video: SkinBioTherapeutics presents and takes questions at the UK Investor Show City forum on December 3

The next City Forum is on January 21 with Adam Reynolds as the guest speaker being quizzed by the Sith Lord Zak Mir. I bet Adam's quaking about that grilling. Three companies will also present and take questions as will Adam. Put the date in your diary. From this week's seminar here is Skinbiotherapeutics (SBTX) presenting and taking questions.

ShareProphets readers tips for 2018 competition - end October update

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

ShareProphets readers tips for 2018 competition - end September update

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

ShareProphets readers tips for 2018 competition - August bank holiday update

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast, Jim Mellon, SalvaRx and the lessons from the todger spray episode

In today's delayed podcast I look at the lessons for SalvaRx (SALV) from the Plethora (PLE) & Regent Pacific episode and ask what is happening at Regent as its shares continue to slide? I also look at the increasingly confused picture at Online Blockchain (OBC) and then ponder why CEO's should not be a guide to share prices or when to sell, ref Optibiotx (OPTI), noting also today's events at Skinbiotherapeutics (SBTX)

Subscribe to ShareProphets to access Premium Content

ShareProphets readers tips for 2018 competition - end July update

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

ShareProphets readers tips for 2018 competition - early-May bank holiday update

Having asked for readers tips for 2018 for the amazing prize of a meal with Tom Winnifrith (or the chance to fob it off on someone you don't like) HERE, the following is a monthly update on performance (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM Casino and the stocks not to have been suspended at the commencement of 2018)...

MIN
MIN

Looking forward to the UK Investor Show – my shopping list

Less than a week to go to the UK Investor Show and it promises to be far and away the best yet. If you’ve not booked a ticket you’d better hurry up – they are running out fast. Lob in the promo code SP10 and you’ll get a freebie investor class ticket  – you can’t say fairer than that! Looking down the list of companies present, I have already compiled a list of who I want to see and also what I am doing on the day.

Wray

UK Investor Show 2017 raises £14,500 for Woodlarks - so far! More to come

There are some people who think the stockmarket and shares business is like robbing a bank - all about making money however you go about it. But at a time of year when many of us think about a man who gave the ultimate gift, his life, for others we think that business should also be about giving. And that brings us to Woodlarks and the UK Investor Show. It started with Paul Scott who donated his, very small, speaker fee...

SkinBioTherapeutics – successful AIM admission for a UK Investor Show ‘Golden Share’

Tom Winnifrith’s ‘Golden Share’ (all proceeds to Woodlarks) from Saturday’s 2017 UK Investor Show has today listed on AIM – and it’s good news…

Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|